­čŹ¬ Cookies

We use cookies to store, access and process personal data to give you the best online experience. By clicking Accept Cookies you consent to storing all cookies and ensure best website performance. You can modify cookie preferences or withdraw consent by clicking Cookie Settings. To find out more about cookies and purposes, read our Cookie Policy and Privacy Notice.

Cookies settings

Cookie Control

What are cookies?

Cookies are small text files that enable us, and our service provides to uniquely identify your browser or device. Cookies normally work by assigning a unique number to your device and are stored on your browser by the websites that you visit as well as third-party service providers for those website. By the term cookies other technologies as SDKs, pixels and local storage are to be considered.

If Enabled

We may recognize you as a customer which enables customized services, content and advertising, services effectiveness and device recognition for enhanced security
We may improve your experience based on your previous session
We can keep track of your preferences and personalize services
We can improve the performance of Website.

If Disabled

We won't be able to remember your previous sessions, that won't allow us to tailor the website according to your preferences
Some features might not be available and user experience reduced without cookies

Strictly necessary means that essential functions of the Website can not be provided without using them. Because these cookies are essential for the properly working and secure of Website features and services, you cannot opt-out of using these technologies. You can still block them within your browser, but it might cause the disfunction of basic website features.

  • Setting privacy preferences
  • Secure log in
  • Secure connection during the usage of services
  • Filling forms

Analytics and performance tracking technologies to analyze how you use the Website.

  • Most viewed pages
  • Interaction with content
  • Error analysis
  • Testing and Measuring various design effectivity

The Website may use third-party advertising and marketing technologies.

  • Promote our services on other platforms and websites
  • Measure the effectiveness of our campaigns

Latest analyses


Facebook share Twitter share
New fresh air in pharmaceutical company Abbott Laboratories

New fresh air in pharmaceutical company Abbott Laboratories

The pharmaceutical and chemical industry has seen significant growth during the coronavirus era. Huge profits due to vaccine purchases have ensured huge profits for companies. Today, the world is more or less getting back to normal and this part of the income began to stagnate. The American pharmaceutical giant Abbott Laboratories had a kind of 'wild ride' in recent months, because they had to withdraw even their infant formula from the shelves. However, after the scandal, the card is turning and this particular company could return to her previous levels in the next weeks.

Q1 results  

Abbott Laboratories released its first quarter results in April, where we saw profit growth of more than a third, with revenue growth of almost 30%. The American conglomerate made a net profit of USD 843 million compared to only USD 615 million in the first quarter last year. Revenues grew to USD 6.34 billion, it grew up 29.7% compared to Q1 last year.

Infant formula shortage in the US

There was a problem in the US at the beginning of the year. In February, Abbott Nutrition had to withdraw three brands of powder formulas from the market: Similac, Similac Alimentum and Elecare. This caused a nationwide shortage of formula in the following months, which lasts from May 2022. The reason for the withdrawal of the products from the shelves was an investigation because of a complain of Cronobacter sakazakii infections among four children who were supposed to have consumed artificial infant formula produced under this brand. Cronobacter sakazakii may be the cause of sepsis infection or meningitis, so the alleged formula may have caused the deaths of two infants, the US Food and Drug Administration announced. Both Abbott and U.S. President Biden tried to solve the shortage from other sources but it was not enough.

The stock drop

During the first quarter, the company's share price rose to higher levels. Compared to industry competitors, the stock value was higher and fears of a decline were eventually confirmed. On May 5, we saw a significant decline and the stock price was at $105. Compared to the April high of $123, this is a drop of as much as 14%. The decline in stock value comes at a time when the company is going through a problem with the withdrawal of infant formula from the shelves and at the same time has to deal with the declining demand for vaccines.


Abbott Laboratories' performance over the past 5 years. (Source: Investing)*

Solving the crisis

The bad situation around a recall of the baby formula happened also because Abbott is the largest infant formula manufacturer in the US. However, the recall of the products was inevitable because 2 babies died. The FDA investigation started after four children were hospitalized with bacterial infections, and that is when they consumed the mentioned formula. These days, however, the situation started to stabilize, which could return the company's stock to previous levels. Abbott Nutrition has resumed production of infant formula in the state of Michigan, so the nationwide crisis should be resolved in the coming weeks. The pharmaceutical sector offers interesting opportunities for investors, and just as stocks are falling, there is an opportunity to buy them cheaper and take advantage of the opportunity.


*Past performance is no guarantee of future results.

 [1] Forward-looking statements are based on assumptions and current expectations, which may be inaccurate, or based on the current economic environment which is subject to change. Such statements are not guarantees of future performance. They involve risks and other uncertainties which are difficult to predict. Results could differ materially from those expressed or implied in any forward-looking statements.

The content of this material constitutes marketing communication and should not be considered as any type of investment advice and/or investment research and/or a solicitation for any transactions. This material was prepared for informational/educational purposes only and does not imply an obligation to perform investment transactions nor does it guarantee or predict future performance. BCM Begin Capital Markets Cy Ltd and its relevant persons including affiliates, agents, directors, or employees do not guarantee the accuracy, validity, timeliness, or completeness of any information/data provided by third parties and assume no liability for any loss arising from any investment made based on the said information/data. Past performance is no guarantee of future results.

More analyses

Profile photo of Lucia ┼Ż├írska

Chief Analyst at ProfitLevel

Lucia ┼Ż├írska

Co-founder of the Mafinn website where she educated the general public about different types of investments. As she says, investing can be clear, understandable and accessible to all, you just need to be aware of how to do it. For this reason she decided to pursue her next career into financial markets. As the chief analyst of the brokerage company ProfitLevel she focuses on this topic more deeply and specifically. At the same time she continues to write professional texts about capital markets for the print and online media, also for blogs.

All analysis My posts Company posts

Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 85.61% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please read the Risk Disclosure